So can someone help explain something to me as a layman. With all the trials that we have completed for Alzheimer’s along with the success we have had with our primary and secondary endpoints, we are now looking for approval based on “other endpoints “ or biomarkers . That being the success of reducing the abeta and tau in the brain as well as or better than Biogen and Lilly.
Does that mean that our endpoints don’t matter anymore or just an added benefit that we improve cognitive performance? Do we have to be better than what is now approved with reducing abeta and tau or just close to them because we are just a pill and we don’t require an infusion every 2 weeks? It seems weird to me if this is accurate that we can get approval based on this rather than all the great results we have had on cognition and all the other side benefits of Blarcamisine.
Market Data 
Markets 
AI
